Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
Rhea-AI Summary
Rapport Therapeutics (Nasdaq:RAPP), a clinical-stage biotech focused on small molecule precision medicines for neurological and psychiatric disorders, will join two investor conferences. Management will host fireside chats at the Jefferies Global Healthcare Conference on June 3, 2026, and the Goldman Sachs Global Healthcare Conference on June 8, 2026. Live and archived webcasts will be available in the Investors section of the company website.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – RAPP
On the day this news was published, RAPP gained 2.74%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Earnings and update | Positive | +7.7% | Q1 2026 results, RAP-219 Phase 2a follow-up and Phase 3 timing details. |
| Apr 21 | Clinical data update | Positive | -2.3% | Phase 2a follow-up data for RAP-219 showing sustained seizure reductions. |
| Apr 01 | Upcoming data presentation | Neutral | +1.2% | Announcement of upcoming Phase 2a RAP-219 data presentation at neurology meeting. |
| Mar 10 | Earnings and pipeline | Positive | -3.0% | 2025 financials, strong RAP-219 efficacy, robust cash and China collaboration terms. |
| Mar 09 | Regional partnership | Positive | +1.0% | Strategic RAP-219 collaboration in Greater China with upfront and milestones. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news shows a mix of aligned and divergent price reactions, with some strong clinical and financial updates not consistently translating into gains.
Over the last few months, Rapport reported multiple catalysts around lead candidate RAP-219 and its financial position. Earnings updates on Mar 10 and May 7 highlighted strong Phase 2a efficacy data, a Phase 3 program in focal onset seizures targeting Q2 2026, and cash extending into the second half of 2029, but price reactions were mixed. Clinical follow-up data presented in April also produced varying stock responses. Against this backdrop, the latest conference-participation news fits into an ongoing pattern of active clinical and investor engagement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON and SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in two upcoming investor conferences.
Jefferies Global Healthcare Conference (New York City) – fireside chat on Wednesday, June 3, 2026, at 8:45 am ET.
Goldman Sachs 47th Annual Global Healthcare Conference (Miami, FL) – fireside chat on Monday, June 8, 2026, at 1:20 pm ET.
Interested parties may access the live and archived webcasts of these fireside chats under the “Investors” section of the company’s website at: https://investors.rapportrx.com.
About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological and psychiatric disorders. The Company’s founders made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain, which form the basis of Rapport’s RAP technology platform. The platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead investigational drug, RAP-219, which is designed to achieve neuroanatomical specificity through selective targeting of a RAP expressed only in discrete regions of the brain. The pipeline is anchored by the Company’s epilepsy portfolio, including FOS and primary generalized tonic-clonic seizures, as well as bipolar mania. The Company is also advancing additional discovery and preclinical programs leveraging its platform, including in chronic pain and migraine and in hearing and vestibular disorders.
Investor Contact
Leigh Salvo
New Street Investor Relations
investors@rapportrx.com
